Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. - Wikidata - wikimedia - TriplyDB

Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.

Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.

http://www.wikidata.org/entity/Q43619839

about

Peripheral arterial disease assessment: wall, perfusion, and spectroscopy Calf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging.Systems biology of vascular endothelial growth factors Dose-dependent neovascularization-promoting effect of adenovirus vector CI-1023 in a rat hindlimb ischaemic model.Gene therapy in the treatment of peripheral arterial disease.Pharmacological revascularisation in coronary and peripheral vascular disease.Angiogenic and antiangiogenic gene therapy.Regeneration of vascularized bone.Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients.Therapeutic angiogenesis in critical limb ischemia.A phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease.Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8.Cellular endocytosis and gene delivery Trimodal rescue of hind limb ischemia with growth factors, cells, and nanocarriers: fundamentals to clinical trials.Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation.Angiogenic gene therapy does not cause retinal pathology.Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo.Quantitative microcomputed tomography analysis of collateral vessel development after ischemic injury.Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.

P2860

Q30434383-173488B0-74D5-4A4A-9746-1ADC902490C7 Q30434965-408D8EC2-F023-4EF1-ADE8-21E88718E41D Q30438979-500639C8-83F0-4F1D-B5EE-81DB1DF71648 Q31114069-ED73E0C7-98FA-472E-A579-21565DD54275 Q34070287-E99DB043-21DE-4ADF-B5F1-1F585EB85D88 Q35906980-659E90E5-118D-476A-9778-1A39BF033124 Q36288905-CD7F5BF5-FDBE-451F-8969-E8DE5349B382 Q36474280-FC292B75-816E-4F6E-B3D4-B2F370BE0901 Q37045424-87C4340B-F13B-4076-A5FB-97E08E9FB160 Q37142832-1B0735AF-A7D8-4A73-B1F5-56D11A6A73D8 Q37344037-D25E667D-5EB5-4E60-9E7A-7F72D114767E Q37599900-FF782E72-8FDA-4716-9E25-E72A1619CD36 Q37747047-DAF8C141-9118-4496-BA4B-14FD0D5302DD Q39240834-0D207888-16DA-4DD7-99AD-41A171976497 Q39685561-B71A22DD-706E-4CD3-8BEE-871B192D107D Q45869416-0B4D09C8-DFA4-4325-ABEA-AA9C8DAAE803 Q45875626-983A472D-6033-4D28-87F6-8A82DE6A1B89 Q47963643-881BE2AD-1D98-496E-B4BB-6745CA6B76AD Q48358527-52EF1074-7849-42E4-82F5-BC651442221F

P2860

Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.

http://www.wikidata.org/entity/Q43619839

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Adenoviral-mediated gene trans ...... results from a phase I trial.

@en

Adenoviral-mediated gene trans ...... results from a phase I trial.

@nl

type

label

Adenoviral-mediated gene trans ...... results from a phase I trial.

@en

Adenoviral-mediated gene trans ...... results from a phase I trial.

@nl

prefLabel

Adenoviral-mediated gene trans ...... results from a phase I trial.

@en

Adenoviral-mediated gene trans ...... results from a phase I trial.

@nl

P1433

Q43619839-EE4EA648-86D8-4957-82DB-3572118EF068

P1476

Q43619839-29C467AC-0D52-4FEB-B83D-71D28BFDAAD6

P2093

Q43619839-28344868-FCB4-49B2-9E50-493E9905F93C

Q43619839-4C7C01E6-86E0-43E4-97B5-983AE9FA4930

Q43619839-5B95B3D1-7234-4D7B-B1A1-66B89AF30AF0

Q43619839-60D42C1C-27A1-4818-A904-B1BFF498766C

Q43619839-7E6B8DA1-1BAB-4934-AA71-8D446CC89A85

Q43619839-B621FB7E-06ED-4883-B504-0A8E4E091F01

Q43619839-B6644E3A-6FE6-4AEE-B154-2B51CC51129F

P2860

Q43619839-2C7814F7-09F4-4742-B236-EB13E4F3A5A5

Q43619839-3651D769-E00B-421B-9180-E082F6EB1DD1

Q43619839-47C378A8-7C7C-4979-9ED0-640FDC740CF4

Q43619839-53FB18D8-243B-4E1E-B20E-DF9111CFA224

Q43619839-7E99A11F-BC9C-4C95-9539-3177F578A7F0

Q43619839-7F03F96A-D67E-46F3-942E-376147C4858C

Q43619839-A4A4BF21-5DB7-40EA-ABE9-AF6EF8C86AC9

Q43619839-B762EDF4-60D6-41CA-A22E-8C476037769F

Q43619839-BCDF30E1-4BA5-4C59-91D6-ED4EB66C2351

Q43619839-D776E392-BFD3-4B79-B743-C242ABBA9830

P304

Q43619839-00756646-323B-41F3-8E2B-89901844B91C

P31

Q43619839-26193279-B286-4C45-B831-FE6C13A856A9

P356

Q43619839-7FAB96FE-2AF1-4601-B5EA-F7E918926ED4

P433

Q43619839-86121E4F-64D8-490C-A14B-D1BB64B8BD23

P478

Q43619839-21A8853D-94CA-4F91-A129-7966E556AF90

P577

Q43619839-0B72F845-EEF7-43F9-960D-55C40558F701

P5875

Q43619839-EA75A6A6-98CC-4D92-8C50-F887AFDF6CC0

P698

Q43619839-4604B6A1-4F9A-42B0-BB16-7E273BEA40AF

P921

Q43619839-3E3A14B1-96C0-4560-AE2E-32FB8FFBACD3

Q43619839-56C00CB7-B277-4AFB-AB3F-727900420C2F

Q43619839-6B387BC6-D872-4EE4-9684-3953D94BCA8D

P356

1358863X03VM460OA

P1433

Vascular Medicine

P1476

Adenoviral-mediated gene trans ...... results from a phase I trial.

@en

P2093

Emile R Mohler

http://www.w3.org/2001/XMLSchema#string

Henrik Rasmussen

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Trachtenberg

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Olin

http://www.w3.org/2001/XMLSchema#string

Raphael Pak

http://www.w3.org/2001/XMLSchema#string

Ronald G Crystal

http://www.w3.org/2001/XMLSchema#string

Sanjay Rajagopalan

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic angiogenesis for ischemic cardiovascular disease.

Assessment of risks associated with cardiovascular gene therapy in human subjects.

Roles of P2-purinoceptors in the cardiovascular system.

Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.

Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review.

Modulation of growth factor action: implications for the treatment of cardiovascular diseases.

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.

Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication.

Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.

Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia.

P304

9-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1191/1358863X03VM460OA

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10656674

http://www.w3.org/2001/XMLSchema#string

P698

12866606

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial